Stockreport

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

AIM ImmunoTech Inc.  (AIM) 
PDF Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-va [Read more]